Farmako, the Frankfurt-based pharmaceutical wholesale company, today announces the succession in the management. Katrin Eckmans, a business graduate with many years of management experience, has taken over the management of the company on 18 July. She already worked as Head of Business Development at Farmako since March 2019. Founder and majority shareholder Sebastian Diemer will also remain heavily involved in the company. The other shareholders Heartbeat Labs and Nikita Fahrenholz will remain on board with a minority share.
"We are convinced that Katrin will lead our company on a new path to success with her experience and leadership qualities," says Sebastian Diemer, founder of Farmako. "Germany is the most important market for medical cannabis in Europe and will continue to grow. The market is also still in the early stages of development throughout Europe and internationally. With our team of currently 10 employees, we are very well positioned to further expand our distribution business with strong suppliers and new products."
Farmako was founded in late 2018 as a pharmaceutical wholesaler specializing in the distribution of pharmaceutical cannabis. Farmako has held the necessary distribution licenses since February 2019, and the company has generated €1.3 million in revenue since March 2019. In July, the shareholders had announced that they would separate the previous business lines and spin off the biosynthesis arm into a separate company with Heartbeat Labs as the majority shareholder.
"After the spin-off of the biosynthesis business, Farmako can again fully concentrate on its actual core business, the trade with medical cannabis and the distribution to pharmacies", says Katrin Eckmans, CEO of Farmako GmbH. "Farmako is an exciting company with a lot of potential and I am very much looking forward to the new task. Together with strong investors and our well-coordinated team, we will continue to help counteract the existing supply shortages and provide more patients with access to necessary cannabis medicines."
After studying business administration, Katrin Eckmans initially worked as an M&A analyst at BNP Paribas before moving into project management in the infrastructure sector. Before joining Farmako, she supported various international projects at Fraport AG for around 10 years, including as a manager for airport acquisitions and investments in Brazil, Greece, Russia and Turkey. She has been Head of Business Development at Farmako since March 2019.
